In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Crispr Therapeutics AG (CRSPResearch Report). The company’s shares closed last Friday at $64.58.

According to, Livshits is a 5-star analyst with an average return of 25.1% and a 61.1% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Intellia Therapeutics.

Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $71.83, a 15.3% upside from current levels. In a report issued on May 17, Oppenheimer also maintained a Buy rating on the stock with a $80.00 price target.

See today’s analyst top recommended stocks >>

Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $157K and GAAP net loss of $69.73 million. In comparison, last year the company earned revenue of $328K and had a GAAP net loss of $48.41 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Source link